FDA lifts ban on Pfizer Lilly pain study
March 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Pfizer, lilly, pain, tanezumab
Pfizer and Eli Lilly will resume Phase III clinical trials of tanezumab following the FDA lifting a ban on trials …
Chief executive promotion at Merck KGaA
March 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Karl-Ludwig Kley, Merck, Merck KGaA, Merck Serono, Stefan Oschmann, chief executive
Merck KGaA is to promote its deputy chief executive Stefan Oschmann to replace Karl-Ludwig Kley in the top job next …
EMA elects new vice-chair
March 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Christa Wirthumer-Hoche, EMA
The European Medicines Agency has elected Dr Christa Wirthumer-Hoche, the head of the Austrian Medicines and Medical Devices Agency, as …
AbbVie invests $30 million to expand in Puerto Rico
March 23, 2015Manufacturing and Production, Sales and Marketing AbbVie, Alzheimer's, Puerto Rico, barceloneta, c2n
AbbVie is investing $30 million to expand one of its sites in Puerto Rico, and is also backing a promising …
Google files patent for cancer combating wearable
March 23, 2015Medical Communications, Sales and Marketing Cancer, Nanoparticle Phoresis, google, google x, nano, oncology, wearable, wipo
Google has filed a patent application for a new cancer-fighting wearable device which it says targets the cells in the …
Pfizer, Novartis and Celgene among late-stage psoriasis trial advances
March 23, 2015Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …
Biogen shortens name and posts positive Alzheimer’s results
March 23, 2015Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec
Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …
Maetrics announces new president
March 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing maetrics, steve cottrell
Maetrics has confirmed that Steve Cottrell, previously its vice president of sales, will now assume the role of president at …
J&J acquires Index Ventures-owned firm XO1
March 23, 2015Sales and Marketing Index Ventures, Isis, J&J, JJ, Janssen, vectura, xo1
Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …
Lilly and Hanmi enter immunological therapy pact
March 20, 2015Research and Development, Sales and Marketing HM71224, Korea, Sjögren, hanmi, immunological, lilly
Eli Lilly and Korean-based pharma firm Hanmi have entered a collaboration agreement to develop and commercialise an immunological therapy. The …
Budget 2015: £1.25 billion boost for mental health services
March 20, 2015Sales and Marketing Budget, Cameron, Miliband, NHS, Osborne, UK
Senior NHS figures have hit out at Chancellor George Osborne’s failure to lay out any specific plans concerning the future …
GSK and Theravance see FDA nod for asthma indication
March 20, 2015Sales and Marketing Advair, AstraZeneca, Dulera, FDA, Foradil, GSK, Merck, Symbicort, Theravance, asthma, breo, budesonide/formoterol fumarate dihydratem, ellipta, fluticasone propionate, formoterol fumarate, mometasone/formoterol
An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …
Actavis gains new Allergan directors
March 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Michael Gallagher, Peter McDonnell
Ireland, Dublin-based pharma firm Actavis has added former Allergan members Michael Gallagher and Dr Peter McDonnell to its board of …
Type 1 diabetes market value to double by 2023
March 19, 2015Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …
Breast cancer treatment market booming
March 19, 2015Research and Development, Sales and Marketing Frost, Herceptin, Kadcyla, Roche, breast cancer, oncology, targeted, tykerb
The increased use of combined targeted therapies for breast cancer is set to lift the market and improve progression-free disease …
AstraZeneca and Daiichi team up for constipation drug
March 19, 2015Sales and Marketing AstraZeneca, Daiichi, Movantik, constipation, naloxegol, oic
AstraZeneca and Daiichi Sankyo have signed a deal worth around $825 million to jointly commercialise constipation drug Movantik in the …
Sanofi diabetes drug fails to show cardio disease benefit
March 19, 2015Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes
A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …
Teva and Ignyta shake hands in oncology deal
March 19, 2015Research and Development, Sales and Marketing CEP-32496, CEP-40125, Levact, RXDX-105, Teva, ignyta, oncology
Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …
MISSION hires chief business officer from Medivir
March 19, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medvir, mission, paul wallace
UK, Cambridge-based cancer biotech MISSION Therapeutics has appointed Dr Paul Wallace as its chief business officer. Having worked in business …
Pharma to profit from Obama reforms
March 18, 2015Sales and Marketing FDA, GlobalData, Obama, US, healthcare, insurance
President Obama’s healthcare reforms will drive massive growth in the US pharma market a new report is predicting. The size …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
